Projected revenue of $16.3 million for the quarter provides insight into the company’s sales performance.
Financial metrics reveal challenges in profitability and cash flow, with a negative P/E ratio of -0.65 and a negative earnings yield of -1.54%.

Fortress Biotech, Inc. (NASDAQ:FBIO) is a biopharmaceutical company that develops and commercializes pharmaceutical and biotechnology products. It operates through a network of subsidiaries and partners, focusing on various therapeutic areas. FBIO competes with other biotech firms in the industry, striving to bring innovative treatments to market.
FBIO is set to release its quarterly earnings on March 27, 2025, with Wall Street estimating an earnings per share (EPS) of -$0.75. The projected revenue for this period is approximately $16.3 million, which provides insight into the company’s sales performance.
FBIO’s financial metrics reveal challenges in profitability and cash flow. The negative price-to-earnings (P/E) ratio of -0.65 and negative earnings yield of -1.54% indicate a lack of profitability. Additionally, the negative enterprise value to operating cash flow ratio of -0.58 suggests difficulties in generating positive cash flow from operations.
Despite these challenges, FBIO’s price-to-sales ratio of 0.74 and enterprise value to sales ratio of 0.94 reflect the company’s valuation relative to its sales. The debt-to-equity ratio of 3.38 indicates a high level of debt compared to equity, while the current ratio of 1.23 suggests reasonable short-term liquidity to cover current liabilities.